Hi, I'm Collin Nzunda!
Molecular Biologist, Bioinformatician, Data Scientist
I am a Molecular Biologist, Bioinformatician, and Data Scientist with a strong foundation in genomic medicine and precision oncology. Currently based at Muhimbili University of Health and Applied Sciences, my work revolves around leveraging next-generation sequencing (NGS) technologies, including Nanopore sequencing, to explore the genetic basis of hematological malignancies such as Chronic Myeloid Leukaemia (CML) and Chronic Lymphocytic Leukaemia (CLL).
I specialize in bioinformatics, data science, and the development of bioinformatics pipelines that combine R, Python, and LaTeX for data analysis, visualization, and scientific communication. My work is focused on providing data-driven insights that improve treatment strategies and patient outcomes in low-resource settings.
-
Hydroxyurea Pharmacogenomics in Sickle Cell Disease
Developing genomic tools for personalized treatment based on hydroxyurea response in Sickle Cell Disease patients using Nanopore sequencing.
Explore the Research -
Genomic Profiling of Leukemias
Comprehensive analysis of somatic mutations in CML and CLL using high-throughput sequencing to inform treatment protocols and improve patient outcomes.
Explore the Research -
TP53 and IGHV CLL in Tanzania
Research on TP53 and IGHV mutations in Chronic Lymphocytic Leukemia patients in Tanzania. Explore the Project -
Reticulocyte Transciptomics(Gene Expression) Analysis Pipeline
Developing bioinformatics pipelines for the Gene Expression Profiling of Reticulocytes: A Transcriptional Exploration of Fetal Hemoglobin for Enhanced Treatment Strategies for sickle cell disease.
Explore the Pipeline
-
Nkya, S., Nzunda, C., Saukiwa, E. et al. Towards genomic medicine: a tailored next-generation sequencing panel for hydroxyurea pharmacogenomics in Tanzania. BMC Med Genomics 17, 190 (2024). DOI: 10.1186/s12920-024-01924-5
-
Nkya, S., Nzunda, C., Saukiwa, E. et al. Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine Approach. DOI: 10.2139/ssrn.4714409